Portal de Periódicos da CAPES

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02

2013; Elsevier BV; Volume: 121; Issue: 11 Linguagem: Inglês

10.1182/blood-2012-09-452375

1528-0020

Xavier Leleu, Michel Attal, Bertrand Arnulf, Philippe Moreau, Catherine Traullé, Gérald Marit, Claire Mathiot, Marie Odile Petillon, Margaret Macro, Murielle Roussel, Brigitte Pegourié, Brigitte Kolb, Anne Marie Stoppa, Bernadette Hennache, Sabine Bréchignac, Nathalie Meuleman, Béatrice Thielemans, Laurent Garderet, Bruno Royer, Cyrille Hulin, Lotfi Benboubker, Olivier Decaux, Martine Escoffre‐Barbe, Mauricette Michallet, Denis Caillot, Jean Paul Fermand, Hervé Avet‐Loiseau, Thierry Façon,

Myeloproliferative Neoplasms: Diagnosis and Treatment

Key Points Combination of pomalidomide with dexamethasone is highly active and can salvage end stage myeloma refractory to lenalidomide and bortezomib. Current data suggest pomalidomide 4 mg/day on days 1 to 21 per 28-days cycle with dexmethasone should be studied in future phase 3 trials.